Cytek Biosciences Statistics Share Statistics Cytek Biosciences has 127.22M
shares outstanding. The number of shares has increased by -3.69%
in one year.
Shares Outstanding 127.22M Shares Change (YoY) -3.69% Shares Change (QoQ) -1.12% Owned by Institutions (%) 60.36% Shares Floating 115.12M Failed to Deliver (FTD) Shares 59 FTD / Avg. Volume n/a
Short Selling Information The latest short interest is 5.65M, so 4.46% of the outstanding
shares have been sold short.
Short Interest 5.65M Short % of Shares Out 4.46% Short % of Float 5.81% Short Ratio (days to cover) 5.67
Valuation Ratios The PE ratio is -140.81 and the forward
PE ratio is -67.08.
Cytek Biosciences's PEG ratio is
2.89.
PE Ratio -140.81 Forward PE -67.08 PS Ratio 4.23 Forward PS 2.3 PB Ratio 2.14 P/FCF Ratio 38.79 PEG Ratio 2.89
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Cytek Biosciences.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 5.86,
with a Debt / Equity ratio of 0.04.
Current Ratio 5.86 Quick Ratio 5.21 Debt / Equity 0.04 Debt / EBITDA -1.7 Debt / FCF 0.78 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $302.34K Profits Per Employee $-9.08K Employee Count 663 Asset Turnover 0.4 Inventory Turnover 2.04
Taxes Income Tax 320K Effective Tax Rate -5.61%
Stock Price Statistics The stock price has increased by -27.15% in the
last 52 weeks. The beta is 1.34, so Cytek Biosciences's
price volatility has been higher than the market average.
Beta 1.34 52-Week Price Change -27.15% 50-Day Moving Average 3.4 200-Day Moving Average 4.63 Relative Strength Index (RSI) 65.7 Average Volume (20 Days) 1,343,449
Income Statement In the last 12 months, Cytek Biosciences had revenue of 200.45M
and earned -6.02M
in profits. Earnings per share was -0.05.
Revenue 200.45M Gross Profit 111.11M Operating Income -20.52M Net Income -6.02M EBITDA -10.03M EBIT -20.52M Earnings Per Share (EPS) -0.05
Full Income Statement Balance Sheet The company has 98.72M in cash and 17.02M in
debt, giving a net cash position of 81.7M.
Cash & Cash Equivalents 98.72M Total Debt 17.02M Net Cash 81.7M Retained Earnings -35.2M Total Assets 493.32M Working Capital 309.56M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 25.38M
and capital expenditures -3.52M, giving a free cash flow of 21.85M.
Operating Cash Flow 25.38M Capital Expenditures -3.52M Free Cash Flow 21.85M FCF Per Share 0.17
Full Cash Flow Statement Margins Gross margin is 55.43%, with operating and profit margins of -10.24% and -3%.
Gross Margin 55.43% Operating Margin -10.24% Pretax Margin -2.84% Profit Margin -3% EBITDA Margin -5.01% EBIT Margin -10.24% FCF Margin 10.9%
